211 related articles for article (PubMed ID: 24249358)
1. Epigenetic regulation of ANKRD18B in lung cancer.
Liu WB; Han F; Jiang X; Yin L; Chen HQ; Li YH; Liu Y; Cao J; Liu JY
Mol Carcinog; 2015 Apr; 54(4):312-21. PubMed ID: 24249358
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic silencing of Aristaless-like homeobox-4, a potential tumor suppressor gene associated with lung cancer.
Liu WB; Han F; Du XH; Jiang X; Li YH; Liu Y; Chen HQ; Ao L; Cui ZH; Cao J; Liu JY
Int J Cancer; 2014 Mar; 134(6):1311-22. PubMed ID: 24037716
[TBL] [Abstract][Full Text] [Related]
3. ANKRD18A as a novel epigenetic regulation gene in lung cancer.
Liu WB; Han F; Jiang X; Yang LJ; Li YH; Liu Y; Chen HQ; Ao L; Cui ZH; Cao J; Liu JY
Biochem Biophys Res Commun; 2012 Dec; 429(3-4):180-5. PubMed ID: 23131552
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
[TBL] [Abstract][Full Text] [Related]
5. NPTX1 is a novel epigenetic regulation gene and associated with prognosis in lung cancer.
Zhou C; Qin Y; Xie Z; Zhang J; Yang M; Li S; Chen R
Biochem Biophys Res Commun; 2015 Mar; 458(2):381-6. PubMed ID: 25646694
[TBL] [Abstract][Full Text] [Related]
6. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
Zhang Y; Miao Y; Yi J; Wang R; Chen L
Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of the GATA genes in lung cancer.
Guo M; Akiyama Y; House MG; Hooker CM; Heath E; Gabrielson E; Yang SC; Han Y; Baylin SB; Herman JG; Brock MV
Clin Cancer Res; 2004 Dec; 10(23):7917-24. PubMed ID: 15585625
[TBL] [Abstract][Full Text] [Related]
9. Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer.
Kong WJ; Zhang S; Guo C; Zhang S; Wang Y; Zhang D
Laryngoscope; 2005 Aug; 115(8):1395-401. PubMed ID: 16094112
[TBL] [Abstract][Full Text] [Related]
10. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
12. WT1 CpG islands methylation in human lung cancer: a pilot study.
Bruno P; Gentile G; Mancini R; De Vitis C; Esposito MC; Scozzi D; Mastrangelo M; Ricci A; Mohsen I; Ciliberto G; Simmaco M; Mariotta S
Biochem Biophys Res Commun; 2012 Sep; 426(3):306-9. PubMed ID: 22925896
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic down-regulation of death-associated protein kinase in lung cancers.
Toyooka S; Toyooka KO; Miyajima K; Reddy JL; Toyota M; Sathyanarayana UG; Padar A; Tockman MS; Lam S; Shivapurkar N; Gazdar AF
Clin Cancer Res; 2003 Aug; 9(8):3034-41. PubMed ID: 12912953
[TBL] [Abstract][Full Text] [Related]
14. IGFBP7 is a p53 target gene inactivated in human lung cancer by DNA hypermethylation.
Chen Y; Cui T; Knösel T; Yang L; Zöller K; Petersen I
Lung Cancer; 2011 Jul; 73(1):38-44. PubMed ID: 21095038
[TBL] [Abstract][Full Text] [Related]
15. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
16. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
[TBL] [Abstract][Full Text] [Related]
17. Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancers.
Xie XM; Zhang ZY; Yang LH; Yang DL; Tang N; Zhao HY; Xu HT; Li QC; Wang EH
Int J Oncol; 2013 Nov; 43(5):1636-42. PubMed ID: 24002585
[TBL] [Abstract][Full Text] [Related]
18. Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines.
Yanada M; Yaoi T; Shimada J; Sakakura C; Nishimura M; Ito K; Terauchi K; Nishiyama K; Itoh K; Fushiki S
Oncol Rep; 2005 Oct; 14(4):817-22. PubMed ID: 16142337
[TBL] [Abstract][Full Text] [Related]
19. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas.
Zhong S; Tang MW; Yeo W; Liu C; Lo YM; Johnson PJ
Clin Cancer Res; 2002 Apr; 8(4):1087-92. PubMed ID: 11948118
[TBL] [Abstract][Full Text] [Related]
20. Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma.
Shimizu D; Kanda M; Nomoto S; Oya H; Takami H; Hibino S; Suenaga M; Inokawa Y; Hishida M; Takano N; Nishikawa Y; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Oncol Rep; 2014 Mar; 31(3):1305-13. PubMed ID: 24366000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
